Skip to content

Role of T-cells in Post-Menopausal Osteoporosis

The Role of T-cells in Women Undergoing Surgical Menopause

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00787904
Enrollment
19
Registered
2008-11-10
Start date
2006-12-31
Completion date
2012-12-31
Last updated
2016-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Keywords

Osteoporosis, T-cells

Brief summary

This is an observational study of women undergoing surgical menopause to determine whether T-cells play an important role in the etiology of post-menopausal osteoporosis. Subjects will examined before and after surgery and followed over a two year period to determine the biology of T-cells during this study period.

Detailed description

Estrogen (E) deficiency is a major cause of post-menopausal osteoporosis. The mechanisms by which E deficiency causes osteoporosis has been recently linked to regulation of two key osteoclastic cytokines: RANKL and TNFα (TNF) , , produced by the T-cell in the bone micro-environment. TNF is a cytokine that has long been associated with bone destruction during E deficiency in both animal and human models. However, the cellular sources of TNF and its exact mechanism of action are poorly understood. Previous studies in animal models has demonstrated that in marked contrast to responses in wild type (WT) mice, ovariectomy (ovx) failed to induce bone loss and did not stimulate osteoclast (OC) formation in T-cell deficient mice. This phenomenon is reversed by T cell reconstitution with WT T cells but not with T cells from TNF -/- mice2,4. These findings established T-cells and T-cell produced TNF as essential mediators of the bone-wasting effects of E deficiency in vivo. TNF further enhances OC formation by up regulating the stromal cell production of RANKL and M-CSF and by augmenting the responsiveness of OC precursors to RANKL4. The mechanisms by which E deficiency leads to enhanced levels of T-cell derived TNF involve a realignment of the adaptive immune response that ultimately leads to an expansion in the pool of TNF secreting T-cells. Dr. Pacifici's group showed that these pathways in mouse models involve the up-regulation of antigen presentation by macrophages and dendritic cells, leading to T cell activation and peripheral expansion of TNF producing T cells. They also showed that E deficiency causes a rebound in thymic T cell output that contributes to both the T cell expansion and the bone loss induced by ovx in young adult mice . The objective of this study is to translate these critical findings in the mouse for the first time to E deficient women following ovx. If this work defines an important role for T-cells in E deficiency-induced bone loss, this could stimulate the development of novel therapies designed to block T-cell expansion or their contribution to cytokine production and thus prevent or attenuate bone loss in this common clinical setting. The hypothesis of the research plan is that T-cells derived from women, rendered E deficient after undergoing ovx, exhibit: 1) increased T-cell activation, and proliferation; 2) enhanced production of pro-osteoclastogenic cytokines RANKL and TNF; and 3) demonstrate increased T-cell output from the thymus that together cause bone loss.

Interventions

None listed

Sponsors

Emory University
CollaboratorOTHER
Atlanta VA Medical Center
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Women between the age of 18-55, pre-menopausal by history (regular spontaneous menstrual bleeding every 21-35 days) or documented FSH \<10, no current estrogen therapy, undergoing hysterectomy with (ovx) or without ovariectomy (control group) for benign gynecologic disease (fibroid uterus, endometriosis, dysfunctional uterine bleeding, chronic pelvic pain) or for prophylaxis against ovarian cancer (BRCA positive).

Exclusion criteria

* History of an active cancer including breast and uterine cancer, treatment with chemotherapy or glucocorticoids * History of an immune deficiency syndrome including HIV infection * History of severe anemia with hematocrit \< 25.

Design outcomes

Primary

MeasureTime frameDescription
Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells2 years(Please note to reviewer, CD3 positivity indicates a T-cell, the title is correct)
Percent Change in Thymus Size Measured by CT Scan2 years

Secondary

MeasureTime frameDescription
Bone Mineral Density2 yearsPlease note that the bone density measurements were done AFTER THE PRIMARY endpoints because bone mineral density changes take longer to see differences

Countries

United States

Participant flow

Participants by arm

ArmCount
Surgical Menopause
Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
6
Surgical Control
Pre-menopausal women undergoing abdominal surgery but without ovary removal
13
Total19

Baseline characteristics

CharacteristicSurgical ControlTotalSurgical Menopause
Age, Continuous41.4 years
STANDARD_DEVIATION 7.1
42.9 years
STANDARD_DEVIATION 6.5
46.3 years
STANDARD_DEVIATION 5.1
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
8 Participants10 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants9 Participants4 Participants
Sex: Female, Male
Female
13 Participants19 Participants6 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 60 / 13
serious
Total, serious adverse events
0 / 60 / 13

Outcome results

Primary

Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells

(Please note to reviewer, CD3 positivity indicates a T-cell, the title is correct)

Time frame: 2 years

ArmMeasureValue (MEAN)Dispersion
Surgical MenopauseChanges in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells3.6 percentage of CD3 positive cellsStandard Deviation 0.5
Surgical ControlChanges in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells1.8 percentage of CD3 positive cellsStandard Deviation 0.2
Primary

Percent Change in Thymus Size Measured by CT Scan

Time frame: 2 years

ArmMeasureValue (MEAN)Dispersion
Surgical MenopausePercent Change in Thymus Size Measured by CT Scan-7 percent changeStandard Deviation 2
Surgical ControlPercent Change in Thymus Size Measured by CT Scan17 percent changeStandard Deviation 4
Secondary

Bone Mineral Density

Please note that the bone density measurements were done AFTER THE PRIMARY endpoints because bone mineral density changes take longer to see differences

Time frame: 2 years

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026